Treating major depressive disorder (MDD) can be challenging since many patients do not respond to initial antidepressant treatment.
Signant’s Clinical Vice President of Mood Disorders Dr. Gary Sachs collaborated with industry colleagues to study the effects of adjunctive cariprazine as treatment for major depressive disorder (MDD).
The results, published in a 2023 issue of the American Journal of Psychiatry, found that cariprazine had a favorable safety and efficacy profile.
Learn more about the study findings by downloading the article below.
